An AI-designed therapy leads to a clinical cure for a major cancer before 2032.
AI drug discovery platforms are targeting oncology pathways. Resolution requires a drug designed primarily by AI to achieve complete remission in clinical trials for a major cancer.
Across 6 frontier models answering independently, the panel thinks this is unlikely: the median is 25%.
They do not agree: GPT puts it at 63% and Qwen at 4%, 59 points apart. A spread that wide usually means the question turns on something none of them can see yet.
Nothing is settled until 15 Sept 2036, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
GPTOpenAI
The key issue is whether an AI-originated oncology asset can show durable complete remissions through pivotal trials by 2036.
- At least several AI-discovered drugs should enter oncology trials by 2030, leaving six years for early efficacy and later-stage readouts.
- Complete remission is already achieved in some major cancers, but durable cure claims require follow-up and strong trial evidence.
- Odds rise sharply if an AI-designed cell therapy or targeted drug posts durable CR data in a registrational study by 2031.
63% -
GeminiGoogle
The timeline hinges on whether current Phase 1/2 AI-designed oncology assets can post documented complete responses before 2032.
- Complete remission in major solid tumors is rare for novel single agents, and oncologic clinical pipelines average over seven years.
- Leading AI biotechs like Insilico and Recursion have entered Phase 2, offering viable shots on goal for early CR endpoints by 2031.
- A Phase 2 readout demonstrating a confirmed complete response in lung or breast cancer by 2029 would double these odds.
28% -
GrokxAI
Whether a current AI-nominated oncology asset posts durable CRs in a major indication by end-2031.
- Insilico, Recursion and peers already have AI-designed molecules in Ph1/2; typical lag to meaningful efficacy data is 4–6 years.
- Solid-tumor complete-remission rates stay low even for targeted drugs; only hematologic precedents have met a clinical-cure bar.
- A 2027–28 Ph2 readout showing >50% MRD-negative CRs in a high-incidence cancer would raise the odds sharply.
28% -
DeepSeekDeepSeek
This turns on whether an AI-originated oncology drug clears Phase 3 with durable complete remissions before 2036.
- AI-designed molecules are already in trials (Insilico's ISM001-055, Recursion's REC-994), but none has yet reached Phase 3 in a major cancer.
- A first-in-class AI drug typically needs 8-12 years from discovery to approval; the 2036 window is tight but not impossible for candidates already in Phase 1.
- The base rate for any single oncology drug achieving a 'clinical cure' (durable complete remission) is under 10%, and AI provenance adds no proven efficacy edge yet.
22% -
ClaudeAnthropic
Hinges on whether any AI-designed oncology drug achieves durable complete remission status in trials by 2036, a very high bar.
- Multiple AI-designed oncology candidates (Insilico, Recursion, Isomorphic) are in early-phase trials but none show curative complete remission signals yet.
- Drug development timelines from Phase 1 to proven curative efficacy typically take 8-12+ years, leaving a tight but plausible window given the 2036 deadline.
- 'Clinical cure' for a major cancer is an extremely high bar rarely met by any single drug regardless of design origin, and attribution to 'AI-designed' adds ambiguity…
10% -
QwenAlibaba
Complete remission from an AI-designed drug in a major cancer requires clearing Phase III by 2031—an almost impossible timeline.
- No AI-designed drug has yet entered Phase III oncology trials; even Insilico's ISM001-055 is only Phase II for IPF, not cancer.
- Phase III oncology trials alone take 3–5 years; a drug would need to be in Phase III by ~2028 to resolve by 2031, and none are close.
- A single dramatic Phase II complete-remission result in a hematologic cancer could shift this, but no such signal has emerged from AI-designed candidates.
4%
6 of 6 models answered · 59 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 18 Sept 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.